Biohaven Pharmaceutical Hold
13F holders, Q2 2025 (June 30)2holders
0new positions
0sold out
$14.11avg. 13F price*
At the end of Q2 2025, 2 institutions reported holding Biohaven Pharmaceutical Hold in their 13F filings, unchanged from Q1 2025. 0 opened new positions and 0 sold out. The largest holders were Knoll Capital Management, LLC ($12.6M) and FNY Investment Advisers, LLC ($32K).
- Company
- Biohaven Pharmaceutical Hold
- CUSIP
- G11196105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 65,890 shares bought, net +65,890 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Knoll Capital Management, LLC | 8.98% | Add +7.8% | 895,269 | $12.6M |
| FNY Investment Advisers, LLC | 0.01% | Add +187.5% | 2,300 | $32K |
"% of holder's portfolio" is BIOHAVEN PHARMACEUTICAL HOLD's weight in each manager's 13F, not the share of Biohaven Pharmaceutical Hold the manager owns.